LINC01877

Across TCGA pan-cancer cohorts, LINC01877 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LINC01877’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC01877 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01877 is over-expressed in tumor, although a few such as THCA and BLCA show the opposite, repressed pattern.

THCA, BLCA, and BRCA are the cancer types where LINC01877 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01877 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.267	<.001	11	view →
BLCA	All	III,IV	−0.077	<.001	9	view →
BRCA	All	III,IV	−0.055	.001	6	view →
UCEC	All	II,III,IV	−0.105	.015	2	view →
CHOL	All	All	−0.061	.008	2	view →
LUSC	Male	II,III,IV	−0.024	.025	1	view →
LUAD	Female	All	−0.022	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LINC01877–THCA

Open the THCA breakdown →